Fig. 4From: TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinomaComparison on tumor immunogenicity and antitumor immunity between TET1-mutated and wild-type patients in the non-ICI-treated cohort. A The abundance of tumor-infiltrating immune cells. B Immune cell markers. C Chemokines, immune checkpoints, and antigen presentation-related molecules. D Cytolytic activity. E The process of antitumor immune responseBack to article page